NASH: Flying The Plane While Building It
Executive Summary
Drug development for nonalcoholic steatohepatitis (NASH), a form of liver disease, is a game of incomplete information: pipeline evolution is occurring in parallel with continued efforts to better understand and manage the disease. To date, no therapy for patients with NASH has been approved and consequences of the condition can be severe, including cirrhosis and hepatocellular carcinoma.
You may also be interested in...
Higher DHA Fatty Acids Linked To Almost 50% Reduction In Alzheimer’s Risk – Framingham Study
Researchers with 1,490 patients in multigenerational cardiovascular study found subjects with higher levels of DHA omega-3s a lower chance of developing Alzheimer’s.
Science Matters: Merck Joins Crowded NASH Race As Several Data Readouts Loom
No NASH treatments are on the market yet, but Phase III data readouts are emerging, mid-stage drugs are demonstrating their capabilities and combinations are in view.
Poxel Adds To NASH Pipeline With Novel Single-Isomer Pioglitazone
Some ground-breaking chemistry has been used to produce a single isomer of pioglitazone, which has been acquired by France's Poxel to evaluate in NASH, adding to its portfolio of potential metabolic disease therapies.